Humulin r u-100, Insuman(insulin human)
Afrezza, Humulin, Insuman, Myxredlin, Novolin (insulin human) is a protein pharmaceutical. Insulin human was first approved as Humulin r u-100 on 1982-10-28. It has been approved in Europe to treat diabetes mellitus.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nutritional and metabolic diseases | D009750 |
| endocrine system diseases | D004700 |
Trade Name
FDA
EMA
Afrezza, Humulin u, Myxredlin, Novolin (discontinued: Humulin u)
CombinationsHumulin, Novolin
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Insulin human
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Humulin R U-500 | insulin human | Eli Lilly | N-18780 RX | 1994-03-31 | 2 products |
| Humulin R U-100 | insulin human | Eli Lilly | N-18780 OTC | 1982-10-28 | 2 products |
| Afrezza | insulin human | Mannkind Corporation | N-22472 RX | 2014-06-27 | 3 products |
| Novolin R | insulin human | Novo Nordisk | N-19938 OTC | 1991-06-25 | 2 products |
Show 1 discontinued
Insulin human
+
Insulin isophane human
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Humulin 70/30 | insulin isophane human and insulin human | Eli Lilly | N-19717 OTC | 1989-04-25 | 3 products |
| Novolin 70/30 | insulin isophane human and insulin human | Novo Nordisk | N-19991 OTC | 1991-06-25 | 2 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| afrezza | Biologic Licensing Application | 2023-02-27 |
| afrezza afrezza | Biologic Licensing Application | 2026-05-30 |
| exubera | 2008-04-08 | |
| humalog 70/30 | New Drug Application | 2010-11-05 |
| humulin | Biologic Licensing Application | 2026-07-01 |
| humulin humulin 70/30 | New Drug Application | 2013-12-18 |
| humulin humulin n | New Drug Application | 2013-12-18 |
| humulin humulin n sterile diluent | New Drug Application | 2013-11-14 |
| humulin sterile diluent | Biologic Licensing Application | 2023-03-07 |
| humulin 70/30 | 2009-03-30 |
Show 9 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
8224 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 19 | 10 | 65 | 31 | 22 | 145 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 10 | 9 | 43 | 21 | 16 | 98 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 30 | 9 | 21 | 2 | 14 | 74 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | 3 | 2 | 1 | 5 | 3 | 14 |
| Hyperglycemia | D006943 | — | R73.9 | 1 | 4 | 3 | 1 | — | 6 |
| Metabolic diseases | D008659 | EFO_0000589 | E88.9 | — | — | 3 | 1 | — | 4 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | — | 4 | — | 4 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | 2 | 1 | — | 3 |
| Gestational diabetes | D016640 | — | O24.4 | — | — | — | 1 | — | 1 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | — | 1 | — | 1 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypoglycemia | D007003 | — | E16.2 | 3 | 3 | 1 | — | 1 | 7 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | 3 | — | — | 3 |
| Glucose metabolism disorders | D044882 | — | — | — | — | 3 | — | — | 3 |
| Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | — | — | 3 | — | — | 3 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | 2 | — | — | 3 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 1 | — | 1 | 2 |
| Overweight | D050177 | — | E66.3 | 1 | — | 1 | — | — | 2 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | 1 | — | — | 1 |
| Asthma | D001249 | EFO_0000270 | J45 | — | — | 1 | — | — | 1 |
| Sepsis | D018805 | EFO_0001420 | A41.9 | — | 1 | 1 | — | — | 1 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 3 | 3 | — | — | — | 6 |
| Colorectal neoplasms | D015179 | — | — | — | 1 | — | — | — | 1 |
| Colonic neoplasms | D003110 | — | C18 | — | 1 | — | — | — | 1 |
| Rectal neoplasms | D012004 | — | — | — | 1 | — | — | — | 1 |
| Head and neck neoplasms | D006258 | — | — | — | 1 | — | — | — | 1 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | — | 1 | — | — | — | 1 |
| Hyperinsulinism | D006946 | — | E16.1 | — | 1 | — | — | — | 1 |
| Carcinoma | D002277 | — | C80.0 | — | 1 | — | — | — | 1 |
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | — | 1 | — | — | — | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 1 | — | — | — | 1 |
Show 3 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 22 | — | — | — | 1 | 23 |
| Glycemic control | D000085002 | — | — | 1 | — | — | — | — | 1 |
| Aggression | D000374 | EFO_0003015 | — | 1 | — | — | — | — | 1 |
| Motor activity | D009043 | EFO_0003940 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | — | — | — | — | 3 | 3 |
| Disease progression | D018450 | — | — | — | — | — | — | 1 | 1 |
| Pancreatitis | D010195 | EFO_0000278 | K85 | — | — | — | — | 1 | 1 |
| Patient participation | D010358 | — | — | — | — | — | — | 1 | 1 |
| Diabetic neuropathies | D003929 | EFO_1000783 | — | — | — | — | — | 1 | 1 |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Insulin human |
| INN | insulin icodec |
| Description | Recombinant human insulin |
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Humulin – Eli Lilly
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
No data
Safety
Black-box Warning
Black-box warning for: Afrezza, Afrezza afrezza
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
40,818 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use